Literature DB >> 17367259

Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin.

Barbara R Sommer1, Howard H Fenn, Terence A Ketter.   

Abstract

Few controlled studies are available to guide the clinician in treating potentially assaultive elderly individuals with psychiatric disorders. Safety concerns limit the use of benzodiazepines and antipsychotic medications in the elderly individual, making anticonvulsants an attractive alternative. This paper reviews three specific anticonvulsants for this purpose: gabapentin, oxcarbazepine and topiramate, describing safety and efficacy in elderly patients with severe agitation from psychosis or dementia. Gabapentin, renally excreted, with a half-life of 6.5-10.5 h, may cause ataxia. Oxcarbazapine, hepatically reduced, may cause hyponatremia, and topiramate may cause significant cognitive impairment. Nonetheless, these are important medications to consider in the treatment of agitation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367259     DOI: 10.1517/14740338.6.2.133

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  9 in total

1.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence.

Authors:  Yunie Kim; Kirsten M Wilkins; Rajesh R Tampi
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report.

Authors:  Thitiporn Supasitthumrong; Blanca M Bolea-Alamanac; Selim Asmer; Vincent L Woo; Petal S Abdool; Simon J C Davies
Journal:  Br J Clin Pharmacol       Date:  2019-02-08       Impact factor: 4.335

Review 4.  The efficacy and safety of newer anticonvulsants in patients with dementia.

Authors:  Christian R Dolder; Kimberly L Nealy
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 5.  Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity.

Authors:  Judith Neugroschl; Sophia Wang
Journal:  Mt Sinai J Med       Date:  2011 Jul-Aug

Review 6.  Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?

Authors:  Damien Gallagher; Nathan Herrmann
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 7.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 8.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

9.  Anticonvulsants in the treatment of aggression in the demented elderly: an update.

Authors:  Benedikt Amann; Johannes Pantel; Heinz Grunze; Eduard Vieta; Francesc Colom; Ana Gonzalez-Pinto; Dieter Naber; Harald Hampel
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-06-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.